Key facts
- This page summarizes Michael Thomas Heffernan's Form 4 filing for Akebia Therapeutics, Inc. (AKBA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jun 2021, 17:27.
Michael Thomas Heffernan - 02 Jun 2021 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)
- Reporting relationship
- Director
- Issuer ticker
- AKBA
- Reported as of
- 02 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2021, 17:27:09 UTC
- Prior SEC filing
- 24 May 2021
- Next SEC filing
- 14 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nicole R. Hadas, attorney-in-fact for Michael T. Heffernan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Thomas Heffernan filed Form 4 for Akebia Therapeutics, Inc. (AKBA) on 03 Jun 2021.
Change
- Previous filing in this sequence was filed on 24 May 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKBA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +13,700
- Change %
- +39%
- Price
- $0.000000
- Shares after
- 48,586
- Date
- 02 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKBA
transaction
Derivative
Stock Option (Right to buy)
Award
- Transaction value
- $0
- Shares
- +20,100
- Change %
- Price
- $0.000000
- Shares after
- 20,100
- Date
- 02 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,100
- Exercise price
- $3.37
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
Footnote F2
The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.